The EGFR mutation detection in NSCLC by Next Generation Sequencing (NGS): cons and pros
S. Rudzinski (Warsaw, Poland), A. Szpechcinski (Warsaw, Poland), J. Moes-Sosnowska (Warsaw, Poland), K. Duk (Warsaw, Poland), A. Zdral (Warsaw, Poland), U. Lechowicz (Warsaw, Poland), P. Rudzinski (Warsaw, Poland), W. Kupis (Warsaw, Poland), E. Szczepulska-Wójcik (Warsaw, Poland), R. Langfort (Warsaw, Poland), T. Orlowski (Warsaw, Poland), J. Chorostowska-Wynimko (Warsaw, Poland)
Source: International Congress 2019 – New molecular signatures in COPD, lung cancer and a1-antitrypsin deficiency
Disease area: Thoracic oncology
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Rudzinski (Warsaw, Poland), A. Szpechcinski (Warsaw, Poland), J. Moes-Sosnowska (Warsaw, Poland), K. Duk (Warsaw, Poland), A. Zdral (Warsaw, Poland), U. Lechowicz (Warsaw, Poland), P. Rudzinski (Warsaw, Poland), W. Kupis (Warsaw, Poland), E. Szczepulska-Wójcik (Warsaw, Poland), R. Langfort (Warsaw, Poland), T. Orlowski (Warsaw, Poland), J. Chorostowska-Wynimko (Warsaw, Poland). The EGFR mutation detection in NSCLC by Next Generation Sequencing (NGS): cons and pros. 4059
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: